
Enric Domingo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9283875/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The clinical features of polymerase proof-reading associated polyposis (PPAP) and recommendations for patient management. Familial Cancer, 2022, 21, 197-209.	0.9	31
2	The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC) Journal of Clinical Oncology, 2022, 40, 3540-3540.	0.8	0
3	Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research, 2022, 28, 4056-4069.	3.2	14
4	Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut, 2021, 70, 544-554.	6.1	148
5	In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 288-300.	3.2	13
6	Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA. Epigenomes, 2021, 5, 6.	0.8	10
7	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. Cancer Research, 2021, 81, 1667-1680.	0.4	32
8	Pulmonary hypertension due to chronic pulmonary thromboembolism. An evolving disease. Revista Espanola De Cardiologia (English Ed), 2021, 74, 368-370.	0.4	0
9	Stromal composition predicts recurrence of early rectal cancer after local excision. Histopathology, 2021, 79, 947-956.	1.6	8
10	Inhibition of WEE1 Is Effective in <i>TP53</i> - and <i>RAS</i> -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 2021, 39, 3705-3715.	0.8	51
11	Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification. Gut, 2020, 69, 1092-1103.	6.1	52
12	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
13	A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular Oncology, 2020, 14, 2384-2402.	2.1	71
14	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	2.0	6
15	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325.	3.2	22
16	TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts. Nature Communications, 2020, 11, 1274.	5.8	64
17	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet, The, 2020, 395, 350-360.	6.3	364
18	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	2.9	41

#	Article	IF	CITATIONS
19	Targeted next generation sequencing reveals a common genetic pathway for colorectal cancers with chromosomal instability and those with microsatellite and chromosome stability. Pathology Research and Practice, 2019, 215, 152445.	1.0	3
20	Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes. European Respiratory Journal, 2019, 53, 1801894.	3.1	0
21	Guidelines for using sigQC for systematic evaluation of gene signatures. Nature Protocols, 2019, 14, 1377-1400.	5.5	23
22	An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis, 2019, 8, 13.	2.1	99
23	Proximal pulmonary arterial wall disease in patients with persistent pulmonary hypertension after successful leftâ€sided valve replacement according to the hemodynamic phenotype. Pulmonary Circulation, 2019, 9, 1-10.	0.8	4
24	POLD1 (DNA polymerase delta 1, catalytic subunit)pages. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, , .	0.1	0
25	POLE (DNA polymerase epsilon, catalytic subunit). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, , .	0.1	0
26	PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, , .	0.1	1
27	Area at risk and collateral circulation in a first acute myocardial infarction with occluded culprit artery. STEMI vs non-STEMI patients. International Journal of Cardiology, 2018, 259, 14-19.	0.8	17
28	The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2018, 2, 1661-1672.	3.4	99
29	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. The Lancet Gastroenterology and Hepatology, 2018, 3, 635-643.	3.7	60
30	Tumour-infiltrating CD8+ lymphocytes as a prognostic marker in colorectal cancer: A retrospective, pooled analysis of the QUASAR2 and VICTOR trials Journal of Clinical Oncology, 2018, 36, 3515-3515.	0.8	4
31	BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer. Cancer Cell, 2017, 31, 79-93.	7.7	83
32	High sensitivity and negative predictive value of theÂDETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Research and Therapy, 2017, 19, 135.	1.6	19
33	Pulmonary arterial wall disease in COPD and interstitial lung diseases candidates for lung transplantation. Respiratory Research, 2017, 18, 85.	1.4	11
34	Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. Nature Communications, 2017, 8, 1998.	5.8	57
35	Pharmacoproteomic characterisation of human colon and rectal cancer. Molecular Systems Biology, 2017, 13, 951.	3.2	44
36	Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	3.6	71

#	Article	IF	CITATIONS
37	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
38	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2016, 17, 1543-1557.	5.1	129
39	Is sidedness prognostically important across all stages of colorectal cancer?. Lancet Oncology, The, 2016, 17, 1480-1482.	5.1	15
40	Abstract 3584: Genomic analysis reveals a role for BCL9L in aneuploidy tolerance in colorectal cancer. , 2016, , .		0
41	Alternative splicing of TIAâ€1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology, 2015, 9, 167-178.	2.1	76
42	The emerging role of the contractile and vascular reserves in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 1756-1758.	3.1	2
43	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. Gut, 2015, 64, 111-120.	6.1	93
44	Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience, 2015, 2, 508-516.	0.9	11
45	'Toxgnostics': an unmet need in cancer medicine. Nature Reviews Cancer, 2014, 14, 440-445.	12.8	29
46	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	0.8	216
47	Evaluation of <i>PIK3CA</i> Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer. Journal of Clinical Oncology, 2013, 31, 4297-4305.	0.8	181
48	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. Journal of Pathology, 2013, 229, 441-448.	2.1	80
49	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. American Journal of Gastroenterology, 2013, 108, 1785-1793.	0.2	120
50	The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Annals of Oncology, 2013, 24, 179-185.	0.6	251
51	Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature Genetics, 2013, 45, 136-144.	9.4	851
52	Replication stress links structural and numerical cancer chromosomal instability. Nature, 2013, 494, 492-496.	13.7	694
53	A study of genomic instability in early preneoplastic colonic lesions. Oncogene, 2013, 32, 5333-5337.	2.6	26
54	DNA polymerase É> and δ exonuclease domain mutations in endometrial cancer. Human Molecular Genetics, 2013, 22, 2820-2828.	1.4	319

4

#	Article	lF	CITATIONS
55	In Vivo Assessment of Pulmonary Arterial Wall Fibrosis by Intravascular Optical Coherence Tomography in Pulmonary Arterial Hypertension: A New Prognostic Marker of Adverse Clinical Follow-Up§. Open Respiratory Medicine Journal, 2013, 7, 26-32.	1.3	23
56	Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 2012, 44, 770-776.	9.4	210
57	Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget, 2012, 3, 1348-1355.	0.8	54
58	Abstract 3105: Chromosome 18q encodes a chromosomal instability suppressor locus in colorectal cancer. , 2012, , .		0
59	<i>KRAS</i> Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clinical Cancer Research, 2011, 17, 1122-1130.	3.2	193
60	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nature Genetics, 2010, 42, 973-977.	9.4	335
61	Clonality Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of Colorectal Adenomas. Gastroenterology, 2010, 138, 1441-1454.e7.	0.6	118
62	Genome-wide association study for germline prognostic markers in colorectal cancer Journal of Clinical Oncology, 2010, 28, 3514-3514.	0.8	0
63	APC and the three-hit hypothesis. Oncogene, 2009, 28, 146-155.	2.6	54
64	A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nature Genetics, 2008, 40, 623-630.	9.4	514
65	Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nature Genetics, 2008, 40, 26-28.	9.4	277
66	Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics, 2008, 40, 1426-1435.	9.4	498
67	Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Human Molecular Genetics, 2008, 17, 3720-3727.	1.4	61
68	Effect of SNP haplotypes associated with colorectal cancer risk on outcome. Journal of Clinical Oncology, 2008, 26, 11079-11079.	0.8	0
69	KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene, 2007, 26, 158-163.	2.6	164
70	A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nature Genetics, 2007, 39, 1315-1317.	9.4	463
71	BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene, 2005, 24, 3995-3998.	2.6	155
72	Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene, 2005, 24, 7630-7634.	2.6	45

#	Article	IF	CITATIONS
73	Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis. Human Molecular Genetics, 2005, 14, 235-239.	1.4	72
74	Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors. Cancer Research, 2005, 65, 10170-10173.	0.4	84
75	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	1.4	127
76	ActivatedBRAFtargets proximal colon tumors with mismatch repair deficiency andMLH1inactivation. Genes Chromosomes and Cancer, 2004, 39, 138-142.	1.5	87
77	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. Journal of Medical Genetics, 2004, 41, 664-668.	1.5	305
78	BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene, 2003, 22, 9192-9196.	2.6	132